Home > Rheumatology > EULAR 2022 > Treatment with bimekizumab beneficial in psoriatic arthritis

Treatment with bimekizumab beneficial in psoriatic arthritis

Presented By
Prof. Iain McInnes, Glasgow University, UK
Conference
EULAR 2022
Trial
Phase 3, BE OPTIMAL
The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a therapy for psoriatic arthritis (PsA). At week 16, over 40% of study participants reached an ACR50 response. Prof. Iain McInnes (Glasgow University, UK) presented the late-breaking phase 3 results of the BE OPTIMAL study (NCT03895203) assessing bimekizumab in PsA patients who did never before receive biologics [1]. The trial enrolled 852 adult patients with at least 1 active PsA lesion and/or diagnosis of psoriasis. As may be expected in a trial for PsA, the baseline features of the cohort included a mean age around 49, under 50% men, and just under 60% on concomitant methotrexate. Also, about 50% of the participants had a body surface area affected by psoriasis of ≥3%. The 16-week double-blind phase consi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on